+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Severe hypercholesterolemia in patients with graft-vs-host disease affecting the liver after stem cell transplantation



Severe hypercholesterolemia in patients with graft-vs-host disease affecting the liver after stem cell transplantation



Endocrine Practice 18(1): 90-97



To review the available literature on severe hypercholesterolemia occurring in the context of graft-vs-host disease affecting the liver. A literature search was conducted in PubMed for articles on hypercholesterolemia occurring in the context of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation. The review included the type of lipid abnormalities observed, complications, and available management strategies. Severe hypercholesterolemia can occur in patients who develop graft-vs-host disease after transplant. We describe 8 patients with severe hypercholesterolemia occurring in the context of graft-vs-host disease affecting the liver after hematopoietic stem cell transplantation (7 from the literature and 1 from our institution). No association was observed with a specific age, sex, type of hematologic malignancy, or use of a specific immunosuppressant. The elevated cholesterol is either due to high concentrations of lipoprotein X or low-density lipoprotein. Unlike low-density lipoprotein, lipoprotein X may not be atherogenic. Treatment may not be required when lipoprotein X is the major elevated lipoprotein unless hyperviscosity occurs, but treatment is indicated when there is elevation in low-density lipoprotein. Plasmapheresis may be necessary. Ultimate treatment is control of the graft-vs-host disease affecting the liver that would improve or completely resolve the hyperlipidemia.

(PDF emailed within 0-6 h: $19.90)

Accession: 055739401

Download citation: RISBibTeXText

PMID: 21940276

DOI: 10.4158/Ep11212.RA


Related references

Liver transplantation for severe hepatic graft-versus-host disease in two children after hematopoietic stem cell transplantation. Transplantation Proceedings 42(10): 4608-4610, 2011

Post-transplant events - Prognostic value of T-1 cell numbers prior to allogeneic stem cell transplantation in patients with severe graft-versus-host disease. Bone Marrow Transplantation 35(7): 691-697, 2005

Organ dysfunction after the preparative regimen predicts for severe graft vs host disease in patients undergoing allogeneic blood stem cell transplantation. Blood 94(10 SUPPL 1 PART 1): 157a, Nov 15, 1999

The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease. International Journal of Molecular Sciences 17(11): -, 2016

Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation. Zhonghua Nei Ke Za Zhi 53(9): 710-714, 2015

Liver transplantation in a child with liver failure due to chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from the same unrelated living donor. Pediatric Transplantation 16(7): E325-E327, 2013

Haploidentical hematopoietic stem cell transplantation for graft-versus-host disease after liver transplantation. Blood 118(12): 3448-3449, 2011

Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children. Biology of Blood and Marrow Transplantation 16(10): 1388-1401, 2011

Total nodal irradiation in patients with severe treatment-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects. RadioTherapy and Oncology 116(2): 287-293, 2016

Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 21(5): 941-944, 2016

Anti-Thymocyte-Globulin as part of the preparative regimen prevents graft failure and severe Graft versus Host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Annals of Hematology 80(4): 209-215, 2001

Polymorphism in the IFN-gamma gene is associated with severe acute graft versus host disease in beta thalassemia major patients undergoing matched related hematopoietic stem cell transplantation (HSCT).. 2007

Risk factors for moderate-to-severe acute graft-vs.-host disease after allogeneic stem cell transplantation in children. Pediatric Transplantation 7(2): 130-136, 2003

Immunosuppressive treatment of severe acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation Proceedings 34(7): 2931-2933, 2002